The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Insights into the current role of BTK inhibitors for treating Waldenström’s in the UK
In this video, Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, discusses the role of BTK inhibitors (BTKis) in treating patients with Waldenström’s macroglobulinemia (WM), highlighting their current use in the United Kingdom. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the Bruton Kinase Inhibitor products, the subsequent generations as well, have really transformed the life of our patients because don’t forget that these patients are of quite variable age. We have quite a lot of older age group of patients. This is oral therapy as well. That is very good for patients’ quality of life and to get on with their life with acceptable toxicity of these agents in using them in the WM practice...
I think the Bruton Kinase Inhibitor products, the subsequent generations as well, have really transformed the life of our patients because don’t forget that these patients are of quite variable age. We have quite a lot of older age group of patients. This is oral therapy as well. That is very good for patients’ quality of life and to get on with their life with acceptable toxicity of these agents in using them in the WM practice. In the UK now, we have a license to use BTK inhibitors as a second or further line. The agent that is licensed and we can use is Zanubrutinib. And this is giving our patients the chance to keep going with good quality of life and good response for a prolonged period as well. That will become increasingly a hot topic in our pathway of treating the WM patients because obviously we have the chemoimmunotherapy in the first-line therapy and then we have the BTK inhibitors. We’re looking forward to the results from the BCL2 inhibitors or combination of BTKi with BCL2 inhibitors that in some countries is more accessible rather than others. And also in this treatment pathway, we cannot completely exclude recycling old-fashioned therapies or in a very small selected subgroup of patients, even considering getting these people into response with old-fashioned therapies and going to autologous transplant based on their performance status and fitness or eligibility criteria to move on to this type of therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
